- Home
- GRVY vs AURA Comparison
GRVY vs AURA Comparison
Compare GRVY & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | AURA |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.1M | 333.4M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GRVY | AURA |
|---|---|---|
| Price | $62.45 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 17.5K | ★ 206.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.12 | $4.73 |
| 52 Week High | $74.75 | $7.73 |
Technical Indicators
Market Signals| Indicator | GRVY | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 47.37 |
| Support Level | $62.10 | $5.08 |
| Resistance Level | $65.27 | $6.12 |
| Average True Range (ATR) | 2.40 | 0.42 |
| MACD | -0.54 | 0.01 |
| Stochastic Oscillator | 6.20 | 48.63 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.